Amgen received approval from the FDA for a second indication with denosumab for the treatment of skeletal-related events in patients with solid tumors that have spread to the bones. The product will be marketed as Xgeva for this indication. Analysts now say that denosumab as Xgeva, and as Prolia for the treatment of osteoporosis, could earn up to $2.4 B annually. There are predictions that Xgeva will be picked up rapidly by oncologists. Thus, Amgen will recieve a major revenue boost after fours years of flat sales performance. See Fierce Biotech and Xconomy.
Posted by Bruce Lehr November 19th 2010.
Comments